Bio­gen slams cov­er­age pro­pos­al for amy­loid-tar­get­ed Alzheimer's drugs in 31-page com­ment

With about two months left be­fore the Cen­ters for Medicare and Med­ic­aid Ser­vices fi­nal­izes its cov­er­age de­ci­sion on amy­loid-tar­get­ed Alzheimer’s drugs, Bio­gen on Thurs­day closed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.